“U.S. biotech companies generally remain quite interested in partnering with Chinese companies because of the enormous market potential and the recognition that the Chinese are increasingly innovative. That is why the industry trade groups are trying to find ways to help address U.S. national security concerns without cutting off the U.S. from the innovations that are occurring in China,” he said.